



Ref: SEC/SE/2013-14
Date: 02.08.2013

To,
Corporate Relation Department
Bombay Stock Exchange Ltd.
1st Floor, Rotunda Building
Dalal Street,
Mumbai – 400 001.

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block Bandra – Kurla Complex
Bandra (E)
Mumbai – 400 051.

MCX Stock Exchange Limited (MCX-SX)
2nd Floor, Exchange Square Suren Road,
Chakala, Andheri (East),
Mumbai - 400093

Re: Information regarding news article about Dabur India Limited

Dear Sir,

We have come to know about the following news item carried out by the media about Dabur India Limited.

"On June 15, 2013, *Business Standard* published a news item "The US Food and Drug Administration (FDA) has imposed an import alert on Dabur India's two manufacturing facilities in Himachal Pradesh."

There were media reports (for example, *Business Today*) on the same day "Dabur takes up import alert with US FDA"

In this context please be informed that we have not received any communication from the US FDA as mentioned in the news article. This is also to clarify that we do not export toothpaste manufactured at our Baddi facility AND fairness cream bleaches manufactured at our Nalagarh facility to USA.

Since the products basis which US FDA might have issued some advisory are not exported by us out of production of these units, we are not in a position to comment any further on this alert, unless we receive any communication from US FDA.

Thanking you

Yours faithfully
For **Dabur India Limited**


(A K Jain)

V P (Finance) & Co. Secretary